Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alkermes Vivitrex gets priority review

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Alkermes' Vivitrex has a Sept. 30 user fee date following FDA's priority review designation for the long-acting naltrexone injection. Vivitrex would be the first once-monthly injection product for treatment of alcoholism; Alkermes has been highlighting the formulation's potential compliance benefit over current alcoholism treatments, most of which are oral (1Pharmaceutical Approvals Monthly April 2005, p. 8). Vivitrex utilizes the company's Medisorb microsphere delivery technology...

You may also be interested in...

Vivitrex 90-day extension

FDA's user fee deadline for Cephalon/Alkermes' once-monthly injectable naltrexone formulation Vivitrex is Dec. 30 following a 90-day extension, the firms announce Sept. 20. The extension stems from a recent response being reclassified as a major amendment. Vivitrex is receiving a priority review for treatment of alcoholism (1Pharmaceutical Approvals Monthly June 2005, In Brief)...

Alkermes Files Vivitrex NDA; Alcoholism Drug May Have Compliance Benefit

Alkermes' Vivitrex is on to track to become the first once-monthly injection for alcohol dependence, providing a potential advantage for patient-compliance monitoring over competitors, the firm says

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts